Physician profile
Elena Kamel
NPI 1790749463
$1,725.71
in general payments reported to CMS, 2019-2025
22 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $116 · 2021: $220 · 2022: $286 · 2023: $198 · 2024: $253 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $685.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $623.76 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $130.75 | 2020-2025 | |
| Aspira Women'S Health INC | $127.60 | 2019 | |
| Hologic Sales and Service, LLC | $120.68 | 2024-2025 | Myosure Tissue Removal Device, Novasure, Aptima |
| Therapeuticsmd, INC. | $105.85 | 2019-2021 | |
| Coopersurgical, INC. | $96.57 | 2019-2025 | Paragard T 380a, Endosee |
| Pfizer INC. | $91.86 | 2023-2025 | |
| Allergan, INC. | $89.35 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $57.56 | 2019 | |
| Mayne Pharma Commercial LLC | $44.15 | 2022-2023 | |
| Biogen, INC. | $39.58 | 2025 | Zurzuvae |
| Astellas Pharma US INC | $28.69 | 2023 | Veozah |
| Avion Pharmaceuticals | $26.34 | 2021 | |
| Dysis Medical, INC. | $24.79 | 2019 | |
| Medicem INC. | $24.25 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $22.66 | 2023 | Truclear |
| Vertical Pharmaceuticals, LLC | $17.11 | 2019 | |
| Organon LLC | $15.23 | 2022 | |
| Novo Nordisk INC | $13.87 | 2023 | Wegovy |
| Minerva Surgical, INC | $13.01 | 2023 | |
| Mission Pharmacal Company | $12.05 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elena Kamel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.